九芝堂(000989.SZ):併購基金與Stemedica簽署補充協議
格隆匯 8 月 7日丨九芝堂(000989.SZ)公佈,公司於2018年5月15日發佈《關於併購基金的投資進展公告》,珠海橫琴九芝堂雍和啟航股權投資基金(有限合夥)(“併購基金”)與美國Stemedica Cell Technologies Inc. (“Stemedica”)簽署《股權投資協議》,併購基金擬以增資的方式向Stemedica投資共計7000萬美元,持有增資擴股後的Stemedica 51%股權。
公司接併購基金通知,為進一步明確雙方權利義務,降低併購基金的交易風險與投資風險,加強對Stemedica的控制,保護併購基金及投資人利益,併購基金與Stemedica就尚未支付的投資款的支付事宜進行了進一步的細化和明確,並於北京時間2020年8月7日簽署了《補充協議》。截至協議簽署日,併購基金實際向Stemedica支付增資人民幣28510萬元(4285萬美元),取得32.05%的股權,剩餘2715萬美元增資款尚未支付。
併購基金與Stemedica簽署該《補充協議》,是為了明確雙方就原《股權投資協議》已經履行完成的義務,並就後續剩餘投資款支付的具體安排達成一致,將《股權投資協議》中併購基金的部分付款義務轉換為認購選擇權。根據本《補充協議》,併購基金已不存在違反《股權投資協議》的投資款支付義務的風險。
《補充協議》的簽訂,屬於併購基金為繼續履行與Stemedica已簽署的《股權投資協議》的補充,旨在保障併購基金的資金安全,防控投資風險,維護併購基金投資者權益。
隨着併購基金根據《補充協議》分期認購股權,公司間接持有Stemedica股權比例將逐步增加,Stemedica的虧損金額對公司淨利潤的影響將增大。同時,隨着併購基金對Stemedica控制力逐步提升,根據會計準則要求,在滿足一定條件後,併購基金可能將Stemedica納入其合併報表。該協議的簽署不會對公司日常生產經營產生重大影響,不存在損害公司及公司其他股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.